APhA - ASP at UT Tyler

As of August 21st of this year, the FDA has officially approved the very first vaccine for use in pregnant women* to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV).

What is RSV?
• RSV is a common cause of illness in children, and infants are among those at highest risk for severe disease, which can lead to hospitalization.

*Abrysvo is approved specifically for use in pregnant individuals at 32 through 36 weeks gestation.

This approval is a huge step in healthcare for pregnant individuals by providing them with the option to protect their infants from this potentially life threatening disease.

For more information, visit https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants